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Abstract
The activity of the enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1),
which converts inactive cortisone (11-dehydrocorticosterone (11-DHC)) (in mice) into
the active glucocorticoid (GC) cortisol (corticosterone in mice), can amplify tissue GC
exposure. Elevated TNFa is a common feature in a range of inflammatory disorders and
is detrimental to muscle function in diseases such as rheumatoid arthritis and chronic
obstructive pulmonary disease. We have previously demonstrated that 11b-HSD1 activity is
increased in the mesenchymal stromal cells (MSCs) by TNFa treatment and suggested that
this is an autoregulatory anti-inflammatory mechanism. This upregulation was mediated
by the P2promoter of theHsd11b1geneandwasdependenton theNF-kB signallingpathway.
In this study, we show that in contrast to MSCs, in differentiated C2C12 and primary murine
myotubes, TNFa suppresses Hsd11b1mRNA expression and activity through the utilization
of the alternative P1 promoter. As with MSCs, in response to TNFa treatment, NF-kB p65
was translocated to the nucleus. However, ChIP analysis demonstrated that the direct binding
was seen at positionK218 toK245 bp of the Hsd11b1 gene’s P1 promoter but not at the P2
promoter. These studies demonstrate the existence of differential regulation of 11b-HSD1
expression in muscle cells through TNFa/p65 signalling and the P1 promoter, further
enhancing our understanding of the role of 11b-HSD1 in the context of inflammatory disease.
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Introduction
The endogenous glucocorticoid (GC) concentrations
are determined by the activity of the hypothalamic–
pituitary–adrenal axis, with tissue and intracellular
exposure further augmented through the activity
of the enzyme 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1), which converts inactive cortisone
(11-dehydrocorticosterone (11-DHC) inmice) to the active
GC cortisol (corticosterone in mice) (Stewart 2003, 2005,
Zhang et al. 2013). The ability of 11b-HSD1 to elevate
cellular GC levels has led it to be implicated in the
modulation of a number of metabolic and inflammatory
disease processes (Hardy et al. 2008, Morgan et al. 2009,
Kaur et al. 2010). Therefore, the identification of factors
and mechanisms regulating 11b-HSD1 expression and
activity could further highlight its physiological and
pathophysiological roles.
Elevation of the pro-inflammatory cytokine TNFa is
a cardinal feature of a range of inflammatory disorders
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(Bamias et al. 2013, Golikova et al. 2013, Khosravi et al.
2013, Moelants et al. 2013). We have previously reported
that TNFa increases 11b-HSD1 expression and activity in
the cells of the mesenchymal lineage, including osteo-
blasts and fibroblasts. In these cells, it was demonstrated
that this was mediated through the classical Hsd11b1 P2
promoter and that the induction of 11b-HSD1 activity by
TNFa was dependent upon NF-kB signalling. However, no
direct binding site of the NF-kB p65 subunit to the P2
promoter could be identified. Basal NF-kB signalling plays
a fundamental role in skeletal muscle myogenesis;
however, during prolonged inflammatory stress,
TNFa-mediated NF-kB activity can abrogate myogenesis,
inhibiting differentiation and increasing catabolic
processes contributing to muscle wasting (Yamaki et al.
2012). Previous research has demonstrated down-
regulation of 11b-HSD1 activity when mature C2C12
muscle cell myotubes are stimulated with TNFa and it
was proposed that NF-kB binding to sites in the Hsd11b1
promoter may be directly responsible for this regulation
(Aubry & Odermatt 2009).
In this study, we demonstrate that in contrast to TNFa
upregulation of 11b-HSD1 in mesenchymal stromal
cells (MSCs) acting through indirect NF-kB regulation at
the P2 promoter, in C2C12 and primary murine myotubes
TNFa stimulates the NF-kB p65 subunit to bind the
alternate Hsd11b1 P1 promoter and mediate inhibition
of 11b-HSD1 activity.
Materials and methods
C2C12 cell culture
Mouse skeletal muscle cell line C2C12 (European Collec-
tion of Cell Cultures (ECACC), Salisbury, Wiltshire, UK )
myoblasts were maintained in DMEM (PAA Laboratories,
Yeovil, Somerset, UK), high-glucose, supplemented with
FBS (10%) penicillin/streptomycin (ten units) and incu-
bated at 37 8C in the presence of 5% CO2. The media were
replaced for every 48 h and the cells were split three times
weekly. To differentiate myoblasts into myotubes, they
were cultivated to 70% confluence before addition of
DMEM, high-glucose, supplemented with 5% horse serum
and penicillin/streptomycin (ten units), and the media
were replaced every 48 h.
Primary mouse muscle cell culture
Primarymuscle dissection and culture ofmyotubes derived
from muscle satellite cells were conducted as reported by
Rosenblatt et al. (1995). Briefly, extensor digitorum longus
(EDL)was dissected frommice at 5weeks of age. Thesewere
digested in type 1 collagenase for 2 h. Individual fibres of
themusclewere thendisrupted gently using a glass pipette.
Individual muscle fibre was then placed into 24-well plates
coated with Matrigel and left for 72 h. After 72 h the
satellite cells had migrated from the fibre and the fibres
were removed from the plate, satellite cell proliferation
media were added. Satellite cells-derived myoblasts were
then cultured to confluence and differentiated to myo-
tubes stable in culture for w14 days. Treatments were for
24 h unless otherwise indicated and occurred in serum-free
media using murine TNFa (10 ng/ml); the vehicle control
used was 0.1% BSA and dexamethasone (1 mM).
RNA extraction, RT-PCR and quantitative real-time PCR
Total RNAwas isolated and extracted from cell lysates using
TRI-Reagent (Sigma–Aldrich). The quality and quantity of
RNArecoveredwereassessedby runningon1.5%agarosegel
and Nanodrop spectrophotometer. RT-PCR used 1 mg RNA
per sample and was carried out using the reverse transcrip-
tion kit (CODE) Applied Biosciences (kit code is 4368814).
Specific mRNA levels were determined using an ABI 7900
sequence detection system (Applied Biosystems). Reactions
were carried out in 12.5 ml volumes on 384 well plates
(Applied Biosystems) in a reaction buffer containing 2!
Taqman Universal PCR Master Mix (Applied Biosystems).
Primers and probes for specific genes were purchased in
‘Assay on Demand’ format from Applied Biosystems
(IGF1:Mm00439560_m1, MYOD:Mm00521984_m1,TP53:
Mm00480750_m1, H6PD:Mm00557617). These were
normalised against 18S rRNA (Applied Biosystems) as an
internal control. Raw data were recovered as CT values and
analysed as per the 2KDDCT method.
RT-PCR of alternative transcripts from the Hsd11b1
gene was carried out as described in Staab et al. (2011).
Western immunoblotting
Protein lysates were collected in RIPA buffer (50 mmol/l
Tris pH 7.4, 1% NP-40, 0.25% sodium deoxycholate,
150 mmol/l NaCl, 1 mmol/l EDTA), 1 mmol/l phenyl-
methylsulfonyl fluoride and protease inhibitor cocktail
(Roche), stored at K80 8C (30 min), defrosted on ice and
centrifuged at 4 8C (10 min, 11 269 g). The supernatantwas
recovered and total protein concentration was assessed
by Bio-Rad assay. Total proteins (25 mg) were resolved on a
12% SDS–PAGE gel and transferred onto a nitrocellulose
membrane. Primary antibodies used were mouse anti-p65
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(Santa Cruz Sc-8008), mouse anti-b-actin (Sigma–Aldrich
A-5441), mouse anti-a-tubulin (Santa Cruz Sc-5286) and
rabbit anti-11b-HSD1 (Ricketts et al. 1998).
Secondary antibodies (Dako, Ely, Cambridgeshire, UK)
anti-mouse and anti-rabbit conjugated with HRP were
added at a dilution of 1/5000. Equal loading of protein
content was verified using b-actin and the bands were
visualised using ECL detection system (GE Healthcare,
Little Chalfont, Buckinghamshire, UK).
Chromatin immunoprecipitation
Chromatin immunoprecipitationwas conducted using the
EZ-ChIP kit from Millipore (Watford, Hertfordshire, UK).
The C2C12 myotubes were differentiated in T175 volumes
flasks. The cells were cross-linked with formaldehyde (1%)
for 10 min at room temperature. Glycine at a final
concentration of 125 mM was added to quench and left
at room temperature for 5 min. The flasks were washed
twice in ice-cold PBS and sonicated using a Bioruptor
(Diagenode, Seraing, Belgium) to produce chromatin
smears with an average size of 500–1000 bp. Chromatin
immunoprecipitations were carried out using the anti-p65
(Santa Cruz Sc-8008) alongside IgG control. DNA recovery
was conducted and SYBR green PCR was carried out using
the primer sequences described in Table 1.
11b-HSD1 activity assay
Briefly, the cells were incubated with 100 nmol/l 11-DHC
and tritiated tracer (3HA) made in-house was added to
each well at 0.22 mCi/reaction. Steroids were then
extracted using dichloromethane, separated using a
mobile phase consisting of ethanol and chloroform
(8:92) by thin layer chromatography and scanned using
a Bioscan 3000 image analyser (Lablogic, Sheffield, South
Yorkshire, UK). The calculations of 11-DHC (A) to
corticosterone (B) were conducted as follows B/(ACB)!
100Z% Conversion.
Statistical analysis
Data shown are meanGS.E.M. of at least three independent
experiments with statistical significance defined as
P!0.05 (*P!0.05; **P!0.01; ***P!0.001) using unpaired
Student’s t-test and were conducted with Prism
(GraphPad, La Jolla, CA, USA). Statistical analysis on
real-time PCR data was carried out on mean DCt values.
Results
TNFa induces p65 nuclear translocation in C2C12 cells
Treatment of cells with TNFa (10 ng/ml) for 1 or 2 h
produced no overall change in p65 cell content. However,
isolation of the nuclear fraction showed enrichment of
p65 in the nucleus upon TNFa stimulation, validating a
functional NF-kB signalling pathway in 5-day-differentiated
C2C12 myotubes (Fig. 1A). To assess archetypal responses
to TNFa, mRNA levels were examined for the cell-cycle
arrest geneTp53 (Trp53) and pro-growth pro-differentiation
genes Igf1 and Myod1 (Fig. 1B). TNFa treatment induced
a significant increase in TP53 and significant decrease in
Igf1 and Myod1 levels, validating the functionality of the
model as has been described previously (Frost et al. 2003,
Langen et al. 2004, Schwarzkopf et al. 2006).
TNFa suppresses 11b-HSD1 mRNA and protein expression
TNFa treatment of C2C12 myotubes decreases 11b-HSD1
mRNA in comparison with controls. Furthermore, analysis
of H6pdh (H6pd) mRNA which is the enzyme that provides
NADPH to support 11b-HSD1 activity showed no change
(Fig. 2A; Lavery et al. 2006). To establish if this response
was detectable at a protein level, myotubes were chal-
lenged with TNFa for 24 h and were examined for levels of
11b-HSD1 protein. TNFa treatment produced a significant
decrease in the expression of 11b-HSD1 protein within
myotubes, compared with vehicle control (Fig. 2B).
TNFa suppresses 11b-HSD1 enzyme activity
It is well established that 11b-HSD1 activity increases
during the process of C2C12 differentiation intomyotubes
Table 1 Primers used for ChIP detection of p65 binding
Putative response element 1
LEFT
ACCTGGGATGAACTGGATTG
Putative response element 1
RIGHT
ACTTTCTGTAGGCCTGTGTGC
Putative response element 2
LEFT
TCTGAGGCAAAGCCAAGACT
Putative response element 2
RIGHT
TAGCCAATCCAGCCATAACC
Putative response element 3
LEFT
GGTGAGCTCCCTTGCACTT
Putative response element 3
RIGHT
AGTTGCAACCCAGCCAGAC
NF-kB IkBa promoter LEFT TAGCCAGCGTTTCCACTCTT
NF-kB IkBa promoter RIGHT GGTCATGCACAGGGAACTTT
K10 kb 11b-HSD flanking LEFT ACTAGCAATGTTCCCGCTGT
K10 kb 11b-HSD flanking RIGHT AATGAGGGAATCTGGGGTTC
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(Aubry &Odermatt 2009). In order to establish the relative
functional impact of TNFa on 11b-HSD1 enzyme activity,
C2C12 cells were differentiated for 4 days and activity
assessed or vehicle/TNFa-treated for a further day (5 day
total). The conversion of 11-DHC to corticosterone by
11b-HSD1 increased from day 4 to day 5 (Fig. 3A).
However, TNFa treatment at day 4 of differentiation for
an additional day significantly reduced 11b-HSD1 activity,
suppressing it to the level of 4-day differentiated cells
(Fig. 3A). We also tested cells with a greater degree of
differentiation, examining C2C12 cells at day 11 and day
12 (Fig. 3B). The conversion rate increased significantly
from day 11 to day 12 and TNFa treatment on day 12
suppressed 11b-HSD1 activity back towards that of
day 11, confirming a robust effect equivalent to the effect
seen at the earlier day 4 and 5 time points. To endorse
these findings, we prepared 7-day differentiated myotubes
from primary EDL muscle. Again, we saw a significant
suppression of 11b-HSD1 activity following 1-day treat-
ment with TNFa, consistent with the data from the fully
differentiated C2C12 cells (Fig. 3C).
These data suggest that the suppression of 11b-HSD1
activity in response to TNFa is unlikely to be due solely
to delays in differentiation, as C2C12 and primary muscle
cells were fully differentiated and may indicate a direct
effect of a TNFa-dependent factor acting at the Hsd11b1
gene promoter to regulate the suppression of 11b-HSD1
expression.
TNFa suppresses 11b-HSD1 at the level of transcription
To establish if the downregulation of 11b-HSD1 occurred
through a transcriptional mechanism, C2C12 myotubes
were treated with TNFa in the presence and absence of
anisomycin to inhibit protein synthesis. Accordingly, the
suppression of 11b-HSD1 mRNA transcription in response
to TNFa is unchanged in the presence of anisomycin,
suggesting that the effect is primarily at the level of
transcription and not the consequence of secondary
protein synthesis (Fig. 4). We used dexamethasone as a
control, as it is well known to induce 11b-HSD1 mRNA
(Fig. 4). However, in the presence of anisomycin, the
Dex-induced 11b-HSD1 increase is attenuated, indicating
a requirement of secondary protein synthesis to elicit
the response.
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Figure 1
Archetypal response of C2C12 myotubes to TNFa. (A) Western blot analysis
of p65 expression in C2C12 myotubes for 1, 2 and 24 h post treatment with
either 0.1% BSA as control or TNFa (10 ng/ml). (B) Real-time PCR analysis of
C2C12 myotube response to TNFa treatment (*P!0.05, **P!0.01).
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Figure 2
TNFa suppresses 11b-HSD1mRNA and protein expression. (A) Real-time PCR
analysis of 11b-HSD1 and H6PDHmRNA in C2C12 myotubes treated for 24 h
with TNFa. (B) Western immunoblot analysis of p65 and b-actin from C2C12
myotubes treated for 24 h with TNFa compared to control. Densitometry of
the western immunoblots were carried out using ImageJ (*P!0.05).
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These data demonstrate that TNFa initiates activation
of a factor not requiring protein synthesis that can act
directly at the 11b-HSD1 promoter, and we hypothesised
that this would most likely be the TNFa target NF-kB.
The Hsd11b1 P1 promoter contains a P65-binding site
Transcription of the Hsd11b1 gene is regulated by two
promoter regions: P1 and P2 (Bruley et al. 2006), and we
confirmed that both promoters were active in our
differentiated C2C12 cells, with promoter P2 usage
preferential to promoter P1 (Fig. 5A). As we hypothesised
that NF-kB binding may be associated with 11b-HSD1
suppression, we conducted ChIP analysis on C2C12 cells
treated with TNFa, assessing p65 binding at putative
response elements in the Hsd11b1 P1 and P2 promoters.
In silico analysis revealed three candidate sequences
with resemblance to a consensus NF-kB-binding site
(GGGACTTTCC), two of which occur within close
proximity to each other and are located in the P1
promoter, upstream of exon 1a transcription start site,
with all three depicted in Fig. 5B. ChIP analysis of samples
amplified with primers for the putative p65-binding
regions following p65 pull down indicated no enrichment
of p65 binding in putative regions 1 and 3 in comparison
with control IgG. However, putative region 2 demon-
strates that TNFa induces an increase in the p65-binding
levels in comparison with control and suggests active
recruitment of the p65 protein to the Hsd11b1 P1
promoter. As a positive control, TNFa-treated C2C12
cells were analysed by ChIP for enrichment of p65 to
a well-validated IkBa-binding site, and confirmatory of
NF-kB activation, further endorsing the finding
of TNFa-mediated NF-kB-binding associated with
suppression of 11b-HSD1 expression and activity
(Fig. 5B). Additionally, a 10 kb upstream sequence of
Hsd11b1 was used to validate the absence of p65 as a
negative control region and no TNFa enrichment was
observed for this sequence (Fig. 5B).
Discussion
Stimulation of 11b-HSD1 activity following TNFa
exposure has been described for early progenitor cells of
the mesenchymal lineage, particularly in cells of human
origin (Zhang et al. 2013). Similarly, in differentiated
cells such as osteoblasts and adipocytes, TNFa increases
11b-HSD1 activity to enhance local GC generation
(Cooper et al. 2001, Tomlinson et al. 2010). Indeed, a
range of cytokines and molecules, including IL1b and
lipopolysaccharide (LPS), can stimulate 11b-HSD1
(Ishii-Yonemoto et al. 2010), suggesting that increasing
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TNFa reduces 11b-HSD1 mRNA independent of the presence of anisomycin.
Myotubes were treated with TNFa or dexamethasone in the presence and
absence of the protein synthesis inhibitor anisomycin. 11b-HSD1mRNAwas
measured by RT-PCR using ribosomal 18S as a standard (*P!0.05).
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Figure 3
TNFa suppresses 11b-HSD1 activity in C2C12 and primary mouse myotubes.
(A) C2C12 control cells were differentiated for 5 days, TNFa treatments
were added 24 h before being assayed for 11b-HSD1 activity. (B) C2C12
control cells were differentiated for 12 days, TNFa treatments were added
24 h before being assayed for 11b-HSD1 activity. Protein lysates from C2C12
cells differentiated for 5 and 12 days (C/K TNFa for 24 h) were subject to
western immunoblots demonstrating p65 expression levels. (C) Primary
myotubes differentiated frommouse EDLmuscle satellite cells were treated
with TNFa or control for 24 h before conducting being assayed for
11b-HSD1 activity (*P!0.05, **P!0.01, ***P!0.001).
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11b-HSD1 is a mechanism to initiate the process of
inflammatory resolution through increased local GC
generation. GCs are well documented to stimulate 11b-
HSD1 expression and activity in most cell types including
myocytes (Morgan et al. 2009). However, followingmuscle
cell TNFa exposure, 11b-HSD1 activity is suppressed,
with the effect mediated through p65 signalling and
independent of secondary protein synthesis.
The best-established transcriptional regulators of
Hsd11b1 gene expression for a range of human and murine
cell types are the members of CCAATT/enhancer-binding
protein (C/EBP) family. Hsd11b1 P1 promoter regulation of
C/EBPa and C/EBPb has been described previously (Balazs
et al. 2008) and C/EBPa is regarded as a positive regulator of
11b-HSD1 transcription in hepatocytes with C/EBPb acting
as a repressor (Ignatova et al. 2009). However, in adipocyte
and adipose tissue, C/EBPb is an activator required to
mediate the GC induction and cytokine regulation of
11b-HSD1 (Sai et al. 2008). More recently it has been
established that an elevated ratio of C/EBPb-liver enriched
inhibitor protein and liver-enriched activator protein
isoforms can downregulate 11b-HSD1 expression (Esteves
et al. 2012). These data collectively represent an evidence
for both the positive and negative regulation of 11b-HSD1
through transcriptional mechanisms in mature cells.
Here, we demonstrate that in both a murine skeletal
muscle cell line and primary cultured myotubes 11b-HSD1
expression and activity are suppressed following TNFa
exposure, with anisomycin experiments attributing this
effect at the level of transcriptional regulation. This led us
to search for potential TNFa-stimulated-NF-kB-binding
motifs in the Hsd11b1 P1 and P2 promoters, using the
cis-regulatory element database (Robertson et al. 2006).
Taking the three strongest targets from the in silico
C
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The NF-kB transcription factor p65 is recruited to the Hsd11b1 P1 promoter
upon stimulation by TNFa. (A) RNA isolated from C2C12 myotubes was
assessed for the expression of Hsd11b1 promoter 1 (P1), promoter 2 (P2),
total and GAPDH transcripts by semi-quantitative RT-PCR. (B) Putative
binding of p65 was measured using ChIP assays carried out on C2C12
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chosen to confirm the absence of specific binding.
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analysis, we used ChIP to identify a p65-binding sequence
in the sequence motif located in the P2 promoter region
(Fig. 5B) and associated this with the down-regulation
of 11b-HSD1.
In contrast to our findings in muscle, adipocytes
from p65 overexpression transgenic mice had elevated
11b-HSD1 at the mRNA and protein level, but show
no evidence for direct gene regulation (Lee et al. 2013).
In this context, NF-kB was acting as a positive regulator
in a model of chronic systemwide p65 activation,
indicating that 11b-HSD1 regulation is complex, with a
number of tissue- and context-specific factors requiring
consideration.
With this in mind, these data presented here represent
the effects mediated following a single acute dose of TNFa,
so biological interpretation in the context of that seen in
another tissue type subjected to chronic TNFa stimulation
should be cautious. TNFa-mediated regulation of 11b-HSD1
is part of a cellular response within muscle that targets a
diverse set of transcriptionally regulated genes (Li et al.
2013). It may be that the suppressive effect observed is
coordinated with the general suppression of myogenic
differentiation, and dependent on interacting transcription
factor and co-regulator availability. We have previously
shown that in myoblasts response to TNFa by 11b-HSD1 is
positively regulated, but in mature myotubes 11b-HSD1 is
negatively regulated. This shift in regulation could in part
be controlled at the level of Hsd11b1 P1 and P2 promoters
utilisation during commitment and progression through
myogenic differentiation that ultimately determines overall
11b-HSD1 expression and activity.
We demonstrate that 11b-HSD1 suppression is
observed in differentiated C2C12 and primary myotubes
and emphasise the important role of coordinated Hsd11b1
P1 and P2 promoters usage to control TNFa-regulated
11b-HSD1 activity. Further experiments are now required
to expand this novel TNFa/NF-kB-mediated transcriptional
suppression of 11b-HSD1 activity in the context of
inflammatory disorders that can severely impact upon
muscle structure and function.
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